R

Read Gene SA
WSE:RDG

Watchlist Manager
Read Gene SA
WSE:RDG
Watchlist
Price: 4.9 PLN 1.66% Market Closed
Market Cap: 57.8m PLN
Have any thoughts about
Read Gene SA?
Write Note

P/E
Price to Earnings

-58.2
Current
-50.8
Median
23
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-58.2
=
Market Cap
57.8m PLN
/
Net Income
-1m PLN
All Countries
Close
Market Cap P/E
PL
Read Gene SA
WSE:RDG
57.8m PLN -58.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -179 080.5
US
Abbvie Inc
NYSE:ABBV
299.8B USD 59
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 37.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.7B USD -259.9
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 910.9
US
Epizyme Inc
F:EPE
94.1B EUR -477.1
AU
CSL Ltd
ASX:CSL
137.3B AUD 33.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
86.2B USD 18.5
US
Seagen Inc
F:SGT
39.3B EUR -55.2
NL
argenx SE
XBRU:ARGX
34B EUR -129.2
Earnings Growth
PL
R
Read Gene SA
WSE:RDG
Average P/E: 211.9
Negative Multiple: -58.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 080.5 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.6
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -259.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -477.1 N/A
AU
CSL Ltd
ASX:CSL
33.5
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.2 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
N/A
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A

See Also

Discover More